Mar Masiá1, Marta Fernández-González2, Guillermo Telenti2, Vanesa Agulló2, José A García2, Sergio Padilla3, Javier García-Abellán2, Antonio Galiana4, Nieves Gonzalo-Jiménez4, Félix Gutiérrez5. 1. Infectious Diseases Unit, Hospital General Universitario de Elche, Alicante, Spain; Clinical Medicine Department, Universidad Miguel Hernández, Alicante, Spain. Electronic address: mmasia@umh.es. 2. Infectious Diseases Unit, Hospital General Universitario de Elche, Alicante, Spain. 3. Infectious Diseases Unit, Hospital General Universitario de Elche, Alicante, Spain; Clinical Medicine Department, Universidad Miguel Hernández, Alicante, Spain. 4. Microbiology Service, Hospital General Universitario de Elche, Alicante, Spain. 5. Infectious Diseases Unit, Hospital General Universitario de Elche, Alicante, Spain; Clinical Medicine Department, Universidad Miguel Hernández, Alicante, Spain. Electronic address: gutierrez_fel@gva.es.
Abstract
OBJECTIVES: Durability of the humoral immune response to SARS-CoV-2 has yet to be defined. We longitudinally evaluated during a 12-month period the antibody responses to SARS-CoV-2, and analysed predictors of antibody titres decline and seroreversion. METHODS: Prospective study conducted in a cohort of patients hospitalized for microbiologically-confirmed COVID-19. Blood and nasopharyngeal samples were sequentially obtained during hospital stay and at 1, 2, 6 and 12 months after patients' discharge for measuring anti-spike (S) and anti-nucleocapsid (N) IgG antibody levels and SARS-CoV-2 RNA, respectively. RESULTS: 80 non-vaccinated patients were analysed. At month 12 after discharge, 73 (91.2%) patients exhibited detectable S-IgG and 35 (43.8%) N-IgG antibody titres. A gradual wane was observed in S-IgG and N-IgG antibody titres. Linear regression showed that S-IgG decline was positively associated with peak antibody titres (coefficient [95% CI] 0.059 [0.05-0.067], p < 0.001), inversely with WHO severity score (coefficient [95% CI] -0.042 [-0.079/-0.004], p = 0.033), and there was a trivial positive association with age (coefficient [95% CI] 0.002 [0-0.005], p = 0.10); N-IgG decline was positively associated with peak antibody titres (coefficient [95% CI] 0.091 [0.078-0.105], p < 0.001). Logistic regression showed that seroreversion for S-IgG was inversely associated with peak S-IgG (OR 0.19; 95% CI, 0.04-0.45; p = 0.004); seroreversion for N-IgG was inversely associated with peak N-IgG (OR 0.71; 95% 0.53-0.90; p = 0.009) and positively with cycle threshold of RT-PCR (OR 1.14; 95% CI, 1.00-1.33; p = 0.062). CONCLUSION: Anti-spike IgG antibodies remain detectable one year after hospitalization for COVID-19. Higher peak antibody titres and disease severity were associated with increased durability of detectable antibodies.
OBJECTIVES: Durability of the humoral immune response to SARS-CoV-2 has yet to be defined. We longitudinally evaluated during a 12-month period the antibody responses to SARS-CoV-2, and analysed predictors of antibody titres decline and seroreversion. METHODS: Prospective study conducted in a cohort of patients hospitalized for microbiologically-confirmed COVID-19. Blood and nasopharyngeal samples were sequentially obtained during hospital stay and at 1, 2, 6 and 12 months after patients' discharge for measuring anti-spike (S) and anti-nucleocapsid (N) IgG antibody levels and SARS-CoV-2 RNA, respectively. RESULTS: 80 non-vaccinated patients were analysed. At month 12 after discharge, 73 (91.2%) patients exhibited detectable S-IgG and 35 (43.8%) N-IgG antibody titres. A gradual wane was observed in S-IgG and N-IgG antibody titres. Linear regression showed that S-IgG decline was positively associated with peak antibody titres (coefficient [95% CI] 0.059 [0.05-0.067], p < 0.001), inversely with WHO severity score (coefficient [95% CI] -0.042 [-0.079/-0.004], p = 0.033), and there was a trivial positive association with age (coefficient [95% CI] 0.002 [0-0.005], p = 0.10); N-IgG decline was positively associated with peak antibody titres (coefficient [95% CI] 0.091 [0.078-0.105], p < 0.001). Logistic regression showed that seroreversion for S-IgG was inversely associated with peak S-IgG (OR 0.19; 95% CI, 0.04-0.45; p = 0.004); seroreversion for N-IgG was inversely associated with peak N-IgG (OR 0.71; 95% 0.53-0.90; p = 0.009) and positively with cycle threshold of RT-PCR (OR 1.14; 95% CI, 1.00-1.33; p = 0.062). CONCLUSION: Anti-spike IgG antibodies remain detectable one year after hospitalization for COVID-19. Higher peak antibody titres and disease severity were associated with increased durability of detectable antibodies.
Authors: Margherita Rosati; Evangelos Terpos; Ioannis Ntanasis-Stathopoulos; Mahesh Agarwal; Jenifer Bear; Robert Burns; Xintao Hu; Eleni Korompoki; Duncan Donohue; David J Venzon; Meletios-Athanasios Dimopoulos; George N Pavlakis; Barbara K Felber Journal: Front Immunol Date: 2021-11-26 Impact factor: 7.561
Authors: Vera S Kichatova; Fedor A Asadi Mobarkhan; Ilya A Potemkin; Sergey P Zlobin; Oksana M Perfilieva; Vladimir T Valuev-Elliston; Alexander V Ivanov; Sergey A Solonin; Mikhail A Godkov; Maria G Belikova; Mikhail I Mikhailov; Karen K Kyuregyan Journal: Microorganisms Date: 2022-02-12
Authors: Antoine Lewin; Gaston De Serres; Yves Grégoire; Josée Perreault; Mathieu Drouin; Marie-Josée Fournier; Tony Tremblay; Julie Beaudoin; Amélie Boivin; Guillaume Goyette; Andrés Finzi; Renée Bazin; Marc Germain; Gilles Delage; Christian Renaud Journal: Can J Public Health Date: 2022-04-05
Authors: Sebastian Wirsching; Laura Harder; Markus Heymanns; Britta Gröndahl; Katja Hilbert; Frank Kowalzik; Claudius Meyer; Stephan Gehring Journal: Front Immunol Date: 2022-04-20 Impact factor: 8.786